Evania-M 5 mg+500 mg (Tablet)
Unit Price: ৳ 20.00 (3 x 10: ৳ 600.00)
Strip Price: ৳ 200.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Empagliflozin metformin hydrochloride |
| Company | Healthcare pharmaceuticals ltd |
Indications
- Treatment of adults with type 2 diabetes mellitus
- Adjunct to diet and exercise
- Uncontrolled diabetes with Metformin
- Combination therapy with other diabetes medications
- Treatment of patients already on Empagliflozin and Metformin separately
Pharmacology
- Inhibitor of Sodium-Glucose Co-Transporter 2 (SGLT2)
- Reduces renal reabsorption of glucose
- Lowers renal threshold for glucose
- Increases urinary glucose excretion
- Biguanide type oral antihyperglycemic drug
- Lowers basal and postprandial plasma glucose
- Does not produce hypoglycemia
- Decreases hepatic glucose production
- Improves insulin sensitivity
Dosage & Administration
- Individualized dosage based on effectiveness and tolerability
- Twice daily with meals
- Gradual dose escalation to reduce gastrointestinal side effects
- Maximum recommended daily dose of Metformin Hydrochloride 2000 mg and Empagliflozin 25 mg
- Extended-release formulations available
- Dosage adjustment for renal impaired patients
- Safety and effectiveness in pediatric patients not established
Interaction
- Increased urine volume and frequency of voids with diuretics
- Increased risk of hypoglycemia with insulin or insulin secretagogues
- Monitoring glycemic control with urine glucose tests not recommended
- Drugs that reduce Metformin clearance may increase accumulation
- Risk of lactic acidosis with carbonic anhydrase inhibitors
- Potential for altered glycemic control with certain drugs
- Alcohol can potentiate the effect of Metformin on lactate metabolism
Contraindications
- Hypersensitivity to Empagliflozin and Metformin
- Acute metabolic acidosis
- Severe renal failure (GFR <30 ml/min)
- Conditions altering renal function
- Tissue hypoxia-related diseases
- Hepatic impairment, acute alcohol intoxication, alcoholism
Side Effects
- Urinary tract infection and female genital mycotic infections
- Diarrhea, nausea/vomiting, flatulence, abdominal discomfort, indigestion, asthenia, headache
- Hypoglycemia, gastrointestinal symptoms, vaginal moniliasis, vulvovaginitis, balanitis, urinary tract infection, thirst, taste disturbance, pruritus, rash, increased urination, increased serum lipids, volume depletion, urticaria, dysuria, increased blood creatinine/GFR, increased haematocrit, diabetic ketoacidosis
Pregnancy & Lactation
- Potential risk to fetus especially in the second and third trimesters
- Not recommended during breastfeeding
Precautions & Warnings
- Risk of lactic acidosis
- Assessment and correction of volume status
- Monitoring for hypotension
- Assessment for signs of metabolic acidosis and ketoacidosis
- Consideration for temporary discontinuation in reduced oral intake or fluid losses
- Increased risk for urinary tract infections and genital mycotic infections
- Risk of hypoglycemia, Vitamin B12 deficiency, increased LDL-C, and lack of conclusive evidence for macrovascular risk reduction
Overdose Effects
- No toxicity seen with single or multiple doses of Empagliflozin within specified limits
- Lactic acidosis is a potential emergency for Metformin overdose
- Treatment should be initiated based on the patient's clinical status
- Haemodialysis as the most effective method for lactate and Metformin removal
Therapeutic Class
- Combination Oral hypoglycemic preparations
Storage Conditions
- Keep below 30°C temperature
- Protected from light and moisture
- Keep out of the reach of children